Some of our press releases are protected by a log-in. These news are marked with a little padlock icon. How our medicines can be prescribed by doctors and the regulatory rules under which we operate differ between countries. Additionally, in most countries we are not permitted to advertise medicines to members of the public. Non-promotional information on our products can therefore only be accessed after registering with Daiichi Sankyo or by using your DocCheck login.
-
Daiichi Sankyo2022-08-18 15:09:25Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with HER2 Positive Metastatic
-
Daiichi Sankyo2022-06-23 16:27:20Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Low Metastatic
-
Daiichi Sankyo2022-06-07 17:50:00DS-6000 Suggests Early Clinical Activity in Patients with Advanced Ovarian Cancer or Renal Cell Carcinoma
-
Daiichi Sankyo2022-06-07 17:41:49ENHERTU® Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2 Low
-
Daiichi Sankyo2022-06-03 15:23:19Patritumab Deruxtecan Continues to Show Promising Clinical Activity in Patients Across Subtypes of Metastatic
-
Daiichi Sankyo2022-02-21 12:51:35ENHERTU® Significantly Improved Both Progression-Free and Overall Survival in DESTINY-Breast04 Trial in
-
Daiichi Sankyo2022-01-17 12:35:39ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated
-
Daiichi Sankyo2021-12-28 09:57:56Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Positive
-
Daiichi Sankyo2021-12-23 09:49:55Patritumab Deruxtecan Granted U.S. FDA Breakthrough Therapy Designation in Patients with Metastatic
-
Daiichi Sankyo2021-12-23 09:48:17DESTINY-Lung04 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Mutant